143 related articles for article (PubMed ID: 35288241)
1. The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.
Ni B; Li Q; Zhuang C; Huang P; Xia X; Yang L; Ma X; Huang C; Zhao W; Tu L; Shen Y; Zhu C; Zhang Z; Zhao E; Wang M; Cao H
Cancer Lett; 2022 Jun; 535():215639. PubMed ID: 35288241
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux.
Ni B; He X; Zhang Y; Wang Z; Dong Z; Xia X; Zhao G; Cao H; Zhu C; Li Q; Liu J; Chen H; Zhang Z
Cell Oncol (Dordr); 2023 Apr; 46(2):315-330. PubMed ID: 36808605
[TBL] [Abstract][Full Text] [Related]
4. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.
Hohenberger P; Bonvalot S; van Coevorden F; Rutkowski P; Stoeckle E; Olungu C; Litiere S; Wardelmann E; Gronchi A; Casali P
Eur J Cancer; 2019 Oct; 120():47-53. PubMed ID: 31479947
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
6. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
[TBL] [Abstract][Full Text] [Related]
7. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
Keung EZ; Raut CP; Rutkowski P
Ann Surg Oncol; 2020 Oct; 27(10):3659-3671. PubMed ID: 32734368
[TBL] [Abstract][Full Text] [Related]
8. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y
Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
Shi YN; Li Y; Wang LP; Wang ZH; Liang XB; Liang H; Zhang L; Li B; Fan LQ; Zhao Q; Ma ZX; Zhao XF; Zhang ZD; Liu Y; Tan BB; Wang D; Wang LL; Hao YJ; Jia N
Medicine (Baltimore); 2017 Nov; 96(46):e8240. PubMed ID: 29145240
[TBL] [Abstract][Full Text] [Related]
11. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
12. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
14. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
17. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
[TBL] [Abstract][Full Text] [Related]
18. LncRNA-HOTAIR activates autophagy and promotes the imatinib resistance of gastrointestinal stromal tumor cells through a mechanism involving the miR-130a/ATG2B pathway.
Zhang J; Chen K; Tang Y; Luan X; Zheng X; Lu X; Mao J; Hu L; Zhang S; Zhang X; Chen W
Cell Death Dis; 2021 Apr; 12(4):367. PubMed ID: 33824300
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of stromal-interacting molecule 1-mediated store-operated Ca
Yang Z; Pan L; Liu S; Li F; Lv W; Shu Y; Dong P
Cancer Sci; 2018 Sep; 109(9):2792-2800. PubMed ID: 29957833
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
